CollPlant Biotechnologies Ltd (NASDAQ:CLGN) Q3 2024 Earnings Conference Call November 27, 2024 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Operator Greetings, and welcome to the CollPlant Biotechnologies Third Quarter 2024 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is ...

-Promising results obtained from the pre-clinical study with CollPlant's commercial sized rhCollagen-based regenerative breast implants, demonstrating significant implant vascularization and rapid ingrowth of native tissue-Innovative breast implant technology designed to address a $3.0 billion market opportunity-Cash and cash equivalents balance as of September 30, 2024 was $15.4 million-Conference call to be held today at 10:00 a.m. U.S. EDT –REHOVOT, Israel, Nov. 27, 2024 /PRNewswire/ -- CollPlant Biotech ...

- Conference call to be held on Wednesday, November 27, 2024 at 10:00 a.m. U.S. EST -REHOVOT, Israel, Nov. 12, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2024 on Wednesday, November 27, 2024, before the opening of the U.S. financ ...

CollPlant Biotechnologies (CLGN) and Stratasys Ltd. (SSYS) recently announced the initiation of a preclinical study with 200cc commercial-sized regenerative implants printed on a Stratasys Origin 3D printer. The study is likely to focus on the ability of implants to grow natural breast tissue and completely degrade over time. As part of the study, 3D printed breast implants consisting of 200cc in the volume of CollPlant's rhCollagen-based bioinks produced on a Stratasys' Origin printer are to be tested. The ...

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q2 2024 Earnings Conference Call August 20, 2024 10:00 AM ET Company Participants Dan Ferry - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants Sean Lee - H.C. Wainwright Jason Kolbert - EF Hutton Operator Welcome to the CollPlant Biotechnologies Investor Conference Call to discuss Financial Results for the Second Quarter of 2024 and Corporate Updates. At this time, all participants are in a listen-only mode. A questio ...

COLLPLANT BIOTECHNOLOGIES LTD. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (U.S. dollars in thousands, except share and per share amounts) (Unaudited) NOTE 3 – INVENTORIES: a. Inventories as of June 30, 2024 and December 31, 2023 consisted of the following: | --- | --- | --- | --- | --- | |----------------------|-------|---------------------------------------------|--------------|----------------| | Work in progress | | June 30, 2024 \n(Unaudited) \n$ 218 | December \n$ | 31, 2023 \n173 | | Finishe ...

- Recently initiated a pre-clinical trial with CollPlant's rhCollagen-based regenerative breast implants, printed with Stratasys' Origin® 3D printer that are 200cc in volume - Breast implants could address a $3.0 billion market opportunity - Cash and cash equivalents balance as of June 30, 2024 was $18.9 million - Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, Aug. 20, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company deve ...

Conference call to be held on Tuesday, August 20, 2024, at 10:00 a.m. U.S. EDT REHOVOT, Israel, Aug. 6, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animalderived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial statements for the second quarter of 2024 on Tuesday, August 20, 2024, before the opening of the U.S. financial mark ...

REHOVOT, Israel, July 29, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animalderived collagen for tissue regeneration and medical aesthetics, today announced the release of its inaugural Environmental, Social and Corporate Governance (ESG) and Sustainability Report covering 2023. Commercial-size implants, CollPlant's 3D bioprinted regenerative breast implants under development Co ...

Bio-printing technology now enables fabrication of 200cc implant size and above to address future commercial demand Interim pre-clinical data shows tissue growth including regeneration of maturing connective tissue as well as neovascularization, synchronized with progressive implant degradation No adverse tissue reaction was observed Large-animal studies with commercial-size implants are currently underway with results expected in Q4 2024 and Q1 2025 REHOVOT, Israel, June 6, 2024 /PRNewswire/ -- CollPlant B ...